Novartis AG

Novartis AG

World Rank (Jan-05-2024)
45
Market Cap (Jan-05-2024)
216.513 Billion USD
World Rank (Jul-30-2023)
45
Market Cap (Jul-30-2023)
220.820 Billion USD
World Rank (Jan-07-2022)
61
Market Cap (Jan-07-2022)
201.260 Billion USD
World Rank (Jan-01-2021)
39
Market Cap (Jan-01-2021)
217.770 Billion USD
Headquarters Country
Switzerland
Nasdaq / NYSE Code
NVS
Market Cap (Mar-08-2026)
305.53
CEO
Vasant Narasimhan
Chairman
Joerg Reinhardt
Founders
Alexander Clavel
Johann Rudolf Geigy-Merian
Employee Count
101,703
Employee Count as of Date
As on 2022
Headquarters City/State
Basel
World Region
Europe
World Subregion
Western Europe
Annual Revenue in USD
46,660 Million USD
Annual Operating Income in USD
9,769 Million USD
Annual Net Income in USD
14,850 Million USD
Annual Results for Period Ending
Dec-2023 ending year
Total Assets in USD
99,945 Million USD
Total Liabilities in USD
53,195 Million USD
Total Equity in USD
46,750 Million USD
Balance Sheet for Period Ending
Dec-2023 ending year
Business Sector
Healthcare
Pharmaceutical
Biotechnology
HealthCare Products
Healthcare Service
Company Website
Novartis - Healthcare and Pharmaceutical Companies in World
Wikipedia
Wikipedia
Yahoo
Yahoo @ NYSE
Facebook
Facebook
Company Profile

Novartis is Switzerland based Multi-National Healthcare and Pharmaceutical company. Novartis Company focus on patented medicines, generic medicines and eye care – segments where they have the innovation power and global scale necessary to compete effectively. At the same time, Novartis is expanding their presence in the emerging markets of Asia, Africa and Latin America, where there is fast-growing demand for access to high- quality medicines and healthcare.

Facts About Company

Novartis annual revenue was 51.83 billion USD for year ending Dec-2022 and annual operating profit was 9.19 billion USD and annual net income was 6.95 billion USD for the same period.

Novartis had over 101,703 employees worldwide as on 2022.

Split of Novartis annual revenue 50,545 billion USD for year ending Dec-2022, Innovative Medicines business segment earned 41,296 million USD revenue and Sandoz business segment earned 9,249 million USD revenue.

Within the Innovative Medicines business segment:
Cardiovascular division earned 4,756 million USD revenue.
Immunology division earned 7,287 million USD revenue.
Neuroscience division earned 5,051 million USD revenue.
Solid Tumors division earned 4,723 million USD revenue.
Hematology division earned 6,452 million USD revenue.
Other Promoted Brands division earned 3,127 million USD revenue.
Established Brands division earned 9,900 million USD revenue.

Annual Results Summary

Novartis AG - Yearly Revenues and Profits - in Billion USD:

Year - EndingRevenueOperating IncomeNet Profit
Dec-202346.669.7614.85
Dec-202243.467.946.95
Dec-202143.9710.0524.02
Dec-202049.8910.158.07
Dec-201948.679.0811.73
Dec-201853.168.1712.61
Dec-201750.138.637.70
Dec-201649.43 6.71
Balance Sheet Summary

Novartis AG - Balance Sheet Summary - in Billion USD:

Year Ending:Total AssetsTotal LiabilitiesTotal Equity
Dec-202399.9453.1946.75
Dec-2022117.4558.0359.42
Dec-2021131.7964.1467.65
Dec-2020132.0575.4656.59
Dec-2019118.3762.8955.47
Dec-2018145.5666.9478.61
Dec-2017133.0758.9174.16
Founded Year
1996
Stock Category
S&P EUROPE 350
Stock Exchange
NYSE
Switzerland
Company SubCategory
Top Healthcare Companies in Europe
Top Technology Companies in Europe
Top Pharmaceutical Companies in Europe
Nasdaq Sector
Health Care
Nasdaq Industry
Biotechnology: Pharmaceutical Preparations

Share